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Abstract: This study investigates the influence of photopigment bleaching on 
autofluorescence lifetimes in the fundus in 21 young healthy volunteers. Three measurements 
of 30° retinal fields in two spectral channels (SSC: 498–560 nm, LSC: 560–720 nm) were 
obtained for each volunteer using fluorescence lifetime imaging ophthalmoscopy (FLIO). 
After dark-adaptation by wearing a custom-made lightproof mask for 30 minutes, the first 
FLIO-measurement was recorded (dark-adapted state). Subsequently, the eye was bleached 
for 1 minute (luminance: 3200 cd/m2), followed by a second FLIO-measurement (bleached 
state). Following an additional 10 minute dark adaptation using the mask, a final FLIO-
measurement was recorded (recovered state). Average values of the fluorescence lifetimes 
were calculated from within different areas of a standardized early treatment diabetic 
retinopathy study (ETDRS) grid (central area, inner and outer rings). The acquisition time in 
the bleached state was significantly shortened by approximately 20%. The SSC did not show 
any significant changes in fluorescence lifetimes with photopigment bleaching, only the LSC 
showed small but significant bleaching-related changes in the fluorescence lifetimes τ1 and τ2 
from all regions, as well as the mean fluorescence lifetime in the central area. The 
fluorescence lifetime differences caused by bleaching were by far less significant than 
pathological changes caused by eye diseases. The magnitudes of fluorescence lifetime 
changes are <10% and do not interfere with healthy or disease related FLIO patterns. Thus, 
we conclude that bleaching is not a relevant confounder in current clinical applications of 
FLIO. 
© 2019 Optical Society of America under the terms of the OSA Open Access Publishing Agreement 
1. Introduction 
Fundus autofluorescence (FAF) intensity imaging has become a well-known diagnostic tool 
in ophthalmology over the past years [1]. Autofluorescence is generated by endogenous 
fluorophores in the ocular fundus. A large proportion of the autofluorescence originates from 
lipofuscin accumulated in the retinal pigment epithelium (RPE) [2], which is a complex 
mixture of bisretinoid fluorophores [3–5]. Spectrally resolved autofluorescence measurements 
in human donor eyes revealed the diversity of fluorophores in age-related macular 
degeneration (AMD) patients and controls [6,7]. The decay of the autofluorescence over time 
can be measured in vivo using the novel method of fluorescence lifetime imaging 
ophthalmoscopy (FLIO) [8,9]. As the fluorescence lifetime is characteristic for each 
fluorophore as well as its molecular environment, FLIO provides additional information 
compared to FAF intensity imaging. FLIO is able to produce repeatable [10] and quantitative 
[11] images. It was developed by Schweitzer et al. [12] based on fluorescence lifetime 
imaging (FLIM) techniques [13] used in microscopy [14]. FLIO contributes significantly to 
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the early detection of diseases in human eyes, as has been shown for diseases such as AMD 
[15], diabetic retinopathy [16], and MacTel [17]. It is likely that this novel technique may 
show changes in the eyes of patients even before permanent morphological damage occurs. 
FLIO also emerges as a promising tool in basic research, as it may contribute to the 
understanding of pathologic mechanisms involved in metabolic diseases [18]. Excitation 
spectra, emission spectra and fluorescence lifetime of endogenous fluorophores at the human 
ocular fundus are compiled elsewhere [8,18,19]. 
The visual pigments of photoreceptors are not significantly fluorescent [20]. However, 
they could influence fluorescence signals measured in a multifluorophore system by a 
spectrally selective absorption of the fluorescence light. Investigating quantitative FAF, 
photoreceptors are typically bleached for 20 to 30 seconds prior to the actual measurement 
[21]. Bleaching reduces the effective photopigment concentration of the photoreceptors, as 
human photopigments are photolabile. The amount of pigment bleached is proportional to its 
quantum catch [22]. After successive bleaching exposures, the regeneration of the 
photopigments can be described by a single exponential function with a time constant of 1 to 
2 minutes [23]. Consequently, the fluorescence intensity signal from layers below the 
photopigments should be stronger if measured directly after bleaching. This may 
consequently reduce the required acquisition time. The same is likely to hold true for FLIO. 
More than 10 known endogenous fluorophores exist in the human retina [18,24,25] but 
the FLIO technique is currently limited to the simultaneous detection of at most three 
spatially resolved fluorescence lifetimes. The approximated fluorescence lifetime in FLIO 
typically does not correspond to a single endogenous fluorophore, as it comprises 
fluorescence information from multiple retinal fluorophores. Hence, the spectrally selective 
absorption of light (both, excitation as well as fluorescence light) by photopigments may 
influence the overall fluorescence lifetime and alter amplitudes of individual fluorophores. 
Nevertheless, the fluorescence lifetime of endogenous fluorophores is not affected by 
bleaching. 
The aim of this work is to investigate the influence of photopigment bleaching on FLIO 
measurements in a group of healthy volunteers. 
2. Materials and methods 
2.1 Participants 
Twenty-one volunteers with an average age of 23.6 ± 3.8 years (43% female), a clear 
crystalline lens, and no history of ocular pathology participated in this study. One eye per 
volunteer was included, refraction errors less than −6 to +6 diopters were accepted. Normal 
intraocular pressure was confirmed by noncontact tonometry. All research procedures were 
performed according to the Declaration of Helsinki. Approval for the study was obtained 
from the ethics committee of the University Hospital Jena. Written informed consent was 
obtained from each volunteer prior to participation in the study. 
2.2 Study design 
Pupils were dilated with 0.5% Tropicamid (Mydriaticum Stulln, Pharma Stulln GmbH, Stulln, 
Germany), and dark adaptation was achieved with the use of a custom-made lightproof mask, 
as described below. The FLIO device was adjusted to the volunteer’s eye before the dark 
adaptation phase was started. After 30 min of dark adaptation, the baseline FLIO 
measurement was recorded, following an exposure to bright light for 1 minute using the 
below-described bleaching device. Subsequently, a second FLIO recording was immediately 
performed. The volunteer was then again asked to wear the custom-made lightproof mask for 
an additional 10 minutes until a final FLIO recording was conducted. 
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2.3 Instrumentation 
A schematic of the FLIO device is shown in Fig. 1, details are described elsewhere 
[11,25,26]. 
 
Fig. 1. Schematic of the FLIO instrument. A 473 nm pulsed laser is fed into a scanning laser 
ophthalmoscope by a monomode fiber to excite retinal autofluorescence. Fluorescence 
emission is transmitted by a multimode fiber to a dichroic mirror (DM), which divides the 
fluorescence signal into a short (498–560 nm) and a long spectral channel (560–720 nm). 
Hybrid photomultiplier tube detectors convert the fluorescence photons into electrical pulses, 
which are then processed using time-correlated single photon-counting (TCSPC). A 
continuous wave (CW) infrared (IR) laser illuminates the fundus for online image registration. 
Blocking filters (BF) protect the detectors from excitation and infrared light. 
It is based on a confocal scanning laser ophthalmoscope (cSLO, HRA-2, Heidelberg 
Engineering GmbH, Heidelberg, Germany). Fundus images (30°, 256 × 256 pixels) are 
recorded in a high-speed mode at 8.8 frames/s. A pulsed diode laser with a wavelength of 473 
nm (BDL-473-SMC, Becker & Hickl GmbH), a pulse width of approximately 89 ps (full-
width-at-half-maximum, FWHM), and a repetition rate of 80 MHz is fiber-coupled (single-
mode) into the cSLO to excite the autofluorescence. The laser power in the corneal plane is 
approximately 150 µW, and, according to Sauer et al. [25], it is almost a factor of 104 below 
the exposure limits set by the ANSI standards for durations of up to 8 h [27]. The 
fluorescence photons are collected by a multimode fiber and split into a short spectral channel 
(SSC; 498–560 nm) and a long spectral channel (LSC; 560–720 nm) by a dichroic mirror 
(edge-wavelength 560 nm) after the excitation wavelength was blocked by an edge filter. The 
detectors (HPM-100-40, Becker & Hickl GmbH) of both channels were connected to a time-
correlated single photon-counting (TCSPC) device (SPC-150, Becker & Hickl GmbH). By 
combining the cSLO and the TCSPC technique [13,28,29] with multiple detectors, FLIO 
generates time-, space-, and spectrum-resolved fluorescence decay data sets. It takes 
approximately 2 min for each FLIO measurement to reach the target of 1000 photons per 
pixel [11] in the macular region in the SSC. The FWHM of the instrument response function 
(IRF) is 172 ps for the SSC, and 153 ps for the LSC. 
To ensure a stringent and smooth measurement and bleaching procedure, it is important to 
minimize the time interval between the bleaching and the FLIO measurement. Bleaching 
stimuli were delivered in a customized mini-ganzfeld sphere, which is able to provide the 
required luminance and can easily be mounted within very close proximity to the chin rest of 
the FLIO. Figure 2(C) demonstrates the bleaching setup for a right eye using a Styrofoam 
head model. 
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 Fig. 2. Custom-made lightproof mask, its optical density, miniaturized bleaching device, and 
the bleaching spectrum. The custom-made lightproof mask used for dark adaptation is shown 
in (A). Its optical density is shown in (B). The miniaturized tube-shaped bleaching device (C) 
consists a high-power white light emitting diode, connected to a standard power supply, a 
Lambertian-scattering plastic hemisphere (concave against the eye, diameter 40 mm) and a 
passive aluminum heat sink. The bleaching device was connected to the side of the FLIO 
device. The bleaching procedure is demonstrated for a right eye using a Styrofoam head 
model. The effective bleaching spectrum (D) was measured with a scanning spectrometer and 
a fiber-connected detector. For a bleaching distance of 20 mm (tube edge - cornea), a 
normalized power of 0.46 mW/cm2 (corresponds to 1379 lx) was measured. The luminance 
was 3200 ± 200 cd/m2. 
The custom-made lightproof mask (Fig. 2(A)) was built based on laser protection glasses, 
which were fortified using multiple layers of blackened paper and black tape. Owing to these 
measures, an optical density of six was achieved for visible light for the mask (Fig. 2(B)). 
The miniaturized tube-shaped bleaching device consists of a high-power, white light, 
emitting diode (WLED; GW5BTF65K00, Sharp Corporation, Osaka, Japan), a Lambertian-
scattering plastic hemisphere, and a passive aluminum heat sink. The WLED acts as backlight 
behind the hemisphere, which has a diameter of 40 mm, with the concave part facing the eye. 
The WLED is connected to a standard power supply. Luminance was adjusted to 3200 cd/m2 
by setting the power supply to 8.6 V and 80 mA, it was also measured by a luminance meter 
(LS-110, Minolta Camera Co. Ltd. Osaka, Japan). The bleaching device was mounted at the 
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outside of the chin and forehead rest of the FLIO device. Thus, the volunteers simply needed 
to turn their head for the bleaching procedure. Figure 2(D) shows the normalized, effective 
bleaching spectrum, in the range of 400 nm to 850 nm. The spectral irradiance Eλ was 
measured with a scanning spectroradiometer in combination with an integration sphere 
(Spectro 320 + ISP 75, Instrument Systems GmbH, Munich, Germany). The dilated pupil was 
assumed to have a maximum diameter of 7 mm. The circular aperture of the integration 
sphere was 7 mm in diameter and was positioned directly in front of the bleaching device. A 
normalized power of 0.46 mW/cm2 was measured at the front of the bleaching device at a 
bleaching distance of approximately 20 mm between the tube edge and the cornea, which 
corresponds to 1379 lx. Eye safety for the bleaching device was estimated in accordance to 
the specified fundamental requirements for optical radiation safety for ophthalmic instruments 
in humans (Ophthalmic instruments - Fundamental requirements and test methods - Part 2: 
Light hazard protection (ISO 15004-2:2007)) for continuous-wave operation. The unweighted 
infrared irradiance at cornea and crystalline lens EIR-CL is defined as 
 
2500
770
IR CLE Eλ λ− = ⋅ Δ  (1) 
and results in EIR-CL = 8.1 x 10−5 mW/cm2, which is a factor of 2.5 x 105 below the 
exposure limit defined by the standard. The weighted visible and infrared irradiance at the 
retina EVIR-R is defined as 
 
1400
380
( )VIR RE E Rλ λ λ− = ⋅ ⋅ Δ  (2) 
where R(λ) is the spectral weighting function for thermal hazard defined by the standard. For 
the bleaching device used in this work, EVIR-R = 0.7 x 10−5 mW/cm2, which is a factor of 1.02 
x 104 below the exposure limit defined by the standard. 
As the FLIO device is about a factor of 104 below the exposure limit, the consecutive use 
of FLIO device and bleaching device in the same session is safe according to the standard. 
Estimation of the photopigment bleaching level was realized based on an equation 
proposed by Hollins and Alpern [30], and modified by Paupoo et al. [31], in accordance to, 
 
1
1
v
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τ
  − + ⋅  
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= ⋅ − +  
 (3) 
where B is the fraction of photopigment bleached at the end of the bleaching procedure of 
duration t, with a retinal illumination Ev. Evp is the steady retinal illuminance that bleaches 
half the pigment, and τp is the time constant of photopigment regeneration. Based on the fact 
that τp increases with age, a time constant of 90 s was employed as proposed by Coile and 
Baker [32] for volunteer ages of approximately 30 years. Several groups have investigated 
and quantified the value of Evp. These studies have produced variable results that ranged 
between 20.000 and 30.000 Td [22,30]. Based on these values, the fraction of the bleached 
photopigment in this work ranged between 83% and 89%. Paupoo et al. [31] also measured 
the regeneration kinetics of photopigment and found an exponential recovery behavior in 
accordance to, 
 
max
( ) 1 e p
t
r t B
r
τ
−
= − ⋅  (4) 
where r is the fraction of pigment recovered. Thus, in this work 89% of bleached 
photopigment is fully recovered after 6 minutes. 
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2.4 Data analysis 
To estimate the fluorescence lifetimes and amplitudes, a multi-exponential approach was used 
to describe the measured data based on the sum of exponential decay curves according to 
 (t) i
t
i
i
I IRF e bτα
−
= ∗ ⋅ +  (5) 
where I is the time-dependent fluorescence intensity, α is the amplitude, τ is the fluorescence 
lifetime, i is the index of the exponential, and b is the background, e.g., from thermal noise of 
the detector or background light. The asterisk denotes a convolution integral. The background 
is fixed to 0.004 photons per pixel, which was experimentally determined for typical 
acquisition times in the dark room where all FLIO measurements were conducted. Three 
exponential functions and a binning with a factor of 2 were applied. To approximate the 
fluorescence lifetime parameters, the global optimum per pixel, characterized by the smallest 
possible figure of merit, was determined using a nonlinear optimization algorithm [33]. The χ2 
error according to Neyman’s approach [34] was used in its reduced form, χr2, as the figure of 
merit, and in accordance to, 
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where m is the number of time channels of the photon histogram, IM(tj) is the number of 
measured photons, Ic(tj) is the number of calculated photons estimated using Eq. (5), and p is 
the number of free parameters in the model. 
The amplitude-weighted, mean fluorescence lifetime τm was then calculated from the 
fluorescence amplitudes and lifetimes as 
 
i i
i
m
i
i
α τ
τ
α
⋅
=

  (7) 
A standardized early treatment diabetic retinopathy study (ETDRS) grid centered at the 
macula [35] was placed by an expert in each FLIO measurement. Its central area, as well as 
inner and outer rings were used for further analyses. This is highlighted in Fig. 3. 
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 Fig. 3. FAF intensity and lifetime images from SSC of a healthy volunteer. FAF intensity (A), 
and corresponding mean FAF lifetime images (B) for dark-adapted (1), bleached (2), and 
recovered (3) states in one healthy volunteer. Although the fluorescence intensity and lifetime 
images were very similar, the acquisition times differed significantly. The central area (C), 
inner ring (IR), and outer ring (OR) from the ETDRS grid were used for the data analysis 
(diameter 1, 3, and 6 mm, respectively). For better comparison, the color scaling is identical 
for the three fluorescence intensities, and the fluorescence lifetime plots. 
For each region (central, IR, OR) from each measurement, the mean values of 
fluorescence amplitudes and lifetimes were used for further statistical evaluation. The 
Shapiro–Wilk test [36] was applied to determine if the values of the fluorescence amplitudes 
and lifetimes obtained from all participants followed a normal distribution. In the case of 
normally distributed measurements, a repeated measure analysis of variance (ANOVA) for 
dependent samples was applied to identify significant differences between dark-adapted, 
bleached, and recovered states. Otherwise, the Friedman test was utilized. The post hoc tests 
applied Bonferroni corrections. 
Data analysis was performed using FLIMX [37], which is documented and freely 
available for download online under the open source BSD–license (http://www.flimx.de). 
SPSS 24 (SPSS, Inc., Chicago, IL, USA) was employed for statistical analyses, including 
ANOVA, Friedman, and post hoc tests. 
3. Results 
Except for the usual random variation between measurements, we could not find any 
systematic changes in the fluorescence intensity images in terms of pattern or contrast among 
the different states. 
Figure 3 illustrates FAF intensity and mean lifetime images following dark adaptation, 
directly after bleaching, and at 10 min after bleaching for one typical study participant. 
Although acquisition times for the FLIO measurements at bleached states were much shorter 
(78 s) than the acquisition times at dark-adapted states (136 s) or recovered states (138 s), the 
number of detected photons and mean fluorescence lifetimes were very similar in all three 
measurements. 
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Figure 4 depicts the FAF mean lifetime τm and its fluorescence lifetime components (τ1 - τ3) of the different bleaching states at different fundus locations in both spectral channels. 
 
Fig. 4. Fluorescence lifetimes of the different bleaching states at different fundus locations. 
The fluorescence lifetimes are presented as mean ± standard deviation for both spectral 
channels in the central area, the inner ring, and the outer ring of the ETDRS grid. Significant 
differences are marked by * (p < 0.05). The differences between dark-adapted and bleached 
states of fluorescence lifetime τ1 in the long spectral channel occurred at trend level for the 
outer ring (p = 0.092). The plots are on a logarithmic scale, and values are rounded to the 
nearest decimal. 
The SSC did not show any significant alterations in the fluorescence lifetimes related to 
bleaching. There also were no significant differences in the fluorescence lifetime between the 
dark-adapted state and the recovered state in the SSC. However, some significant differences 
were found in the LSC. Fluorescence lifetimes τ1 and τ2 were slightly but significantly longer 
in the bleached state measurements compared to either dark-adapted state, and/or recovered 
state measurements. This applied to all three regions in the LSC. In the central area of the 
LSC, significant differences were also found for τm (dark-adapted state compared to bleached 
state: p = 0.026; bleached state compared to recovered state: p = 0.01). However, all of these 
fluorescence lifetime changes were less than 10%, which is only a minor alteration. 
Figure 5 shows Bonferroni-corrected confidence intervals (confidence level 95%) of the 
pairwise fluorescence lifetime differences between the different bleaching states at different 
fundus locations, as recommended by the CONSORT Group [38]. The confidence intervals 
indicate the precision of the estimated bleaching effect on the fluorescence lifetimes. 
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Significant differences, indicated by the confidence interval not including zero, are found in 
different fluorescence lifetime measures, including the mean fluorescence lifetime τm between 
the dark-adapted state and bleached state in the LSC. 
 
Fig. 5. Bonferroni-corrected confidence intervals (confidence level 95%) of the pairwise 
fluorescence lifetime differences between the different bleaching states at different fundus 
locations. The scale for confidence intervals of the fluorescence lifetime τ3 is adjusted for 
better visibility (red). The confidence interval not including zero indicates a significant 
difference. 
The average acquisition times for dark-adapted (128 s) and recovered (132 s) states were 
very similar, while the bleached measurements required significantly less time (104 s, p < 
0.05) to obtain a similar amount of photons. On average, measurements in the bleached state 
were approximately 20% faster than measurements in dark-adapted and recovery states. To 
correct for a possible variation in detected fluorescence intensity of the different 
measurements, the total number of detected photons per pixel was divided by the acquisition 
time, averaged over the region of interest, and then averaged over the volunteers to obtain an 
approximate of acquisition speed per measurement (Fig. 6). 
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 Fig. 6. Average acquisition speeds for the different bleaching states at the different fundus 
locations. The acquisition speeds are plotted as mean ± standard deviation for both spectral 
channels in the central area, the inner ring, and the outer ring of the ETDRS grid. Significant 
differences are marked by * (p < 0.05). 
4. Discussion 
The novel technique of fluorescence lifetime imaging is transitioning from a research device 
to a clinically used application, and basic research studies to improve the understanding of 
this technique are indispensable. As it is impossible to control for light exposure in a clinical 
setting, the understanding if or how light may potentially influence the FLIO method is 
necessary. This work particularly describes the effect of light bleaching at high light 
intensities compared to extensive dark adaptation on FLIO. 
Overall, bleaching of the human retina significantly shortens the acquisition time, but has 
no effect on the fluorescence lifetimes within the SSC. A very small but significant effect on 
the fluorescence lifetimes within the LSC was found. This prolongation, depicted in Fig. 4, is 
minor compared to the overall lifetime and likely falls within lifetime changes that are 
accepted in other studies as normal variation. In previous studies, the inter-individual 
variability of fluorescence lifetime values quantified with the coefficient of variation were 
found to be between 6% and 17% [11]. All of the fluorescence lifetime changes reported with 
regards to bleaching were less than 10%. Therefore, it is reasonable to argue that these 
alterations will not or only marginally affect clinical applications. 
Nevertheless, as we found these significant changes, it is appropriate to discuss why FAF 
lifetimes may be slightly altered with bleaching. One may argue that the macular pigment, 
retinal carotenoids accumulating in the fovea, may have an impact. However, these pigments 
are distributed in an area of 1 mm in diameter at the fovea due to the presence of macular 
pigment binding proteins, and their fluorescence emission is mostly found in the SSC 
[24,25,39]. The SSC shows no significant changes in the fluorescence lifetime with 
bleaching. Additionally, photobleaching of the macular pigment itself is not known [40]. 
Since significant differences in fluorescence lifetimes were predominantly found in the 
central macula within the LSC, different bleaching characteristics for rods and cones might be 
assumed. The white bleaching light, however, should bleach all photopigments in a similar 
way. Furthermore, the minor prolongation of fluorescence lifetimes in the LSC might be 
explained by a higher contribution of retinal pigment epithelium fluorescence to the overall 
fluorescence signal of the retina in this spectral channel. The regeneration of photopigments 
causes an accumulation of bisretinoid pigments in the RPE cells known as lipofuscin, which 
are fluorescent byproducts of the visual cycle [4,5,41,42]. Lipofuscin emits a bi-exponential 
fluorescence decay signal with a mean fluorescence lifetime of 1352 ps [18], which is longer 
than the fluorescence lifetime τ2 and shorter than the fluorescence lifetime τ3 in our 
measurements. A2E, one of the lipofuscin bisretinoids, possesses a short fluorescence lifetime 
component of 170 ps [18]. In addition to lipofuscin, the RPE emits a fluorescence signal from 
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melanosomes with a short fluorescence lifetime found by Miura et al. [43] and Peters et al. 
[44]. They took samples from young pigs, which have almost no lipofuscin in their RPE cells 
and no macular pigment [45]. Therefore, a fluorescence signal from lipofuscin with a longer 
fluorescence lifetime is not present in their data. Thus, a higher contribution of the RPE 
fluorescence signal, originating from melanosomes and lipofuscin, caused by bleaching of the 
photopigments could prolong the fluorescence lifetimes τ1 and τ2. Therefore, the bisretinoid 
accumulation might be an interesting theory to follow upon. However, our study population 
shows a mean age of 24 years, where bisretinoid accumulations are unlikely to play a 
significant role. 
The similarity of fluorescence lifetimes as well as acquisition times between dark-adapted 
and recovery measurements confirm our theory that the photoreceptor pigments are largely 
regenerated during the 10 minutes of recovery time. This finding is in accordance to the 
literature [22,23]. 
In addition to the bleaching of the photopigments, any other protein-based fluorophore in 
the retina may be also photobleached. Dynamic photobleaching processes chemically destroy 
fluorescent molecules upon exposure to excitation light [46]. As a result, these molecules lose 
their ability to fluoresce. Fluorescence measurement techniques used in microscopy, such as 
fluorescence photobleaching recovery [47], are based on this effect. In vitro studies revealed 
that irradiation of A2E, a characterized lipofuscin bisretinoid [48], was associated with photo-
oxidation, photoisomerization, and photodegradation [49–51], resulting in reduced A2E 
fluorescence which did not fully recover within 24 hours. A2-PE, another bisretinoid, also 
seems to be susceptible to photochemical reactions [52]. In addition, it cannot be excluded 
that bleaching processes of the light sensitive fluorophore riboflavin might influence our 
results. The fluorescence spectrum of riboflavin is located primarily in LSC. 
The results of our study suggest that dynamic light exposure and associated 
photobleaching of retinal fluorophores does not interfere with FLIO measurements. In 
addition, photobleaching of fluorophores would likely result in a reduced fluorescence 
intensity signal, whereas we found an increased signal for the bleached state. Although 
significantly longer fluorescence lifetimes were found in the bleached state compared to the 
dark-adapted or recovered state, mostly for the intermediate fluorescence lifetime component 
τ2, the relevance of these differences is highly questionable. These changes presented in the 
order of only a few picoseconds, which is negligible compared to the differences found 
between controls and patients in recent clinical studies. A comparison is reported in Table 1. 
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Table 1. Fluorescence lifetime changes in patients with different diseases compared to the 
present worka 
Disease Parameter Change in fluorescence 
lifetime 
Region for 
comparison 
(this work) 
Effect of bleaching 
(this work) 
AMD with geographic 
atrophy [53] 
τm +418 ps in atrophic areas 
vs. surrounding tissue 
OR +5 ps (LSC) 
AMD with reticular 
pseudodrusen and / or soft 
drusen [54] 
τm +175 ps in patients vs. 
controls 
OR +5 ps (LSC) 
Nonexudative AMD [15] τm +79 ps in patients vs. 
controls 
OR +5 ps (LSC) 
Diabetes without diabetic 
retinopathy [16] 
τ3 +280 ps in patients vs. 
controls 
OR +16 ps (LSC) 
Non-proliferative diabetic 
retinopathy [55] 
τm +25 ps in patients vs. 
controls 
C +8 ps (LSC) 
Branch retinal artery 
occlusion [56] 
τ1 +85 ps in ischemic areas 
vs. unaffected areas 
OR +6 ps (LSC) 
Central retinal artery 
occlusion [57] 
τm +89 ps in patients vs. 
controls 
IR +6 ps (LSC) 
Macular holes without 
operculum [58] 
τm +63 ps in patients vs. 
controls 
C +8 ps (LSC) 
Stargardt’s disease [59] τm +149 ps in 
hyperfluorescent flecks vs. 
surrounding tissue 
+77 ps in atrophic areas 
vs. surrounding tissue 
OR +5 ps (LSC) 
Macular Telangiectasia 
Type 2 [17] 
τm +90 ps in patients (early 
stage) vs. controls 
IR +3 ps (SSC) 
Retinitis Pigmentosa [60] τm +89 ps in patients vs. 
controls 
IR +6 ps (LSC) 
Retinitis Pigmentosa [61] τm +118 ps in patients vs. 
controls 
OR +5 ps (LSC) 
 
Even small differences in fluorescence lifetimes of patients compared to healthy subjects, 
such as in patients with non-proliferative diabetic retinopathy, still are larger than bleaching-
related differences. 
Furthermore, it is important to point out that photopigment bleaching in this work was 
very intensive, using high amounts of light to make sure that bleaching is effective. The 
bleaching-related differences reported in this work are expected to be much larger than any 
differences caused by different ambient light conditions in a clinical environment. One may 
argue that previous clinical imaging may play a role in terms of photopigment bleaching. 
However, we were able to show that bleaching effects are reversible within a few minutes, 
which often accounts for the time patients take to transition between different imaging 
devices. Thus, the bleaching state of the photopigments is considered to have no major 
influence on fluorescence lifetimes measured in the clinical setting. Future FLIO studies that 
rely on very small differences in the fluorescence lifetime, e.g. studies investigating early 
disease detection, may have to consider the photopigment bleaching state of the patients in 
the study design. 
There are some limitations in our study. It was impossible to document the exact time 
delay between bleaching and the FLIO measurement immediately after bleaching. This time, 
although not documented, was less than 10 seconds. The photoreceptor pigments may also be 
bleached by the excitation laser during the first 20–30 s of each (dark-adapted) FLIO 
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measurement, which is short in comparison to FLIO’s average acquisition time of circa 130 s. 
Thus, the effect of bleaching on FLIO is considerably small. The effect may increase with 
shorter acquisition times, which should be considered in the ongoing discussion of shortening 
the FLIO acquisition time. The acquisition times in general are not directly comparable 
between FLIO measurements, as each measurement is manually stopped by the operator once 
the threshold of 1000 photons per pixel is reached. The course of the photon count rates over 
time during FLIO measurements could not be recorded owing to technical limitations. This 
might be helpful in future measurements to evaluate if a possible bleaching caused by the 
FLIO device increases the fluorescence signal from the RPE. The validity of such assumption 
is based on the expectation that the photon count rates would increase exponentially during 
the first seconds of the dark-adapted measurements, in a similar manner to the findings 
reported by Theelen et al. [62]. The results of our study are reported in a very young group of 
volunteers. Findings might be different for older volunteers or for patients, especially with 
pathologic changes in the photoreceptor system and the lipofuscin content. 
We also want to note two difficulties regarding to the estimation of photopigment 
bleaching level. First, the use of a single (photopic) light measurement cannot correctly 
calculate the bleaching for both, the red-sensitive and green-sensitive (M and L) cones. 
However, the approach should be reasonably accurate in the case of white light, as was used 
in this study for bleaching. Second, with pupil dilation, calculations employing raw troland 
values are bound to overestimate the absorption of light by the cones because of the Stiles–
Crawford effect [63]. Thus, much of the light that enters the pupil near its rim will be 
ineffective in exciting (or bleaching) the cones, yet will be included in the troland calculation. 
In future work, the bleaching effect of FLIO’s excitation laser will be investigated by 
bleaching using the excitation wavelength, in comparison to bleaching with white light. 
5. Conclusion 
Differences in fluorescence lifetimes caused by photopigment bleaching are comparable to 
general inter-individual variations. It therefore is safe to conclude that bleaching has a 
negligible influence on FLIO measurements. Bleaching of retinal photoreceptors will not 
interfere with FLIO patterns that were reported for various eye diseases. Thus, patients should 
not be bleached prior to FLIO measurements to keep their stress levels as low as possible. 
However, it is reasonable to suggest that FLIO users should attempt to follow an acquisition 
protocol in research studies to obtain the most reliable results with regards to photopigment 
bleaching state. Within 10 minutes of any light exposure patients may experience in the 
clinical routine, fluorescence lifetime characteristics will return to baseline values. Overall, 
photopigment bleaching likely has no influence on the outcome and overall FLIO 
measurement in the clinical setting. 
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